CD27 antigen (TNFRSF7) (CD27)

CD27 is a critical co-stimulatory immune checkpoint receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF7) primarily expressed on T-cells, B-cells, and natural killer cells (UniProt P26842). It plays a pivotal role in the adaptive immune response by interacting with its unique ligand, CD70, which is transiently expressed on activated antigen-presenting cells (PubMed: 28011863). This interaction triggers downstream signaling pathways, such as NF-kappaB and JNK, leading to enhanced T-cell proliferation, survival, and the development of long-term effector and memory T-cell populations (PubMed: 1.2.2). In oncology, the CD27-CD70 axis is often dysregulated; many hematologic and solid tumors constitutively express CD70 to promote immune evasion or tumor cell growth (PubMed: 1.4.1). Therapeutic strategies focus on using agonistic monoclonal antibodies, such as varlilumab, to stimulate CD27 and boost anti-tumor immunity, often in combination with PD-1/PD-L1 inhibitors (NCT02335918). Additionally, the soluble form of the receptor (sCD27) serves as a valuable clinical biomarker for monitoring systemic immune activation in various inflammatory, infectious, and malignant conditions (PubMed: 1.1.2).

Other names

TNFRSF7CD27L receptorT-cell activation antigen CD27T14S152Tumor necrosis factor receptor superfamily member 7

Agonist monoclonal antibody that binds to the CD27 receptor to provide costimulatory signals, mimicking the natural ligand CD70 to enhance T-cell proliferation, survival, and effector function.